JOHN GUINN: Open Payments
NPI 1386060010 · EL DORADO, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$710 in 32 payments from 7 companies in 2025. Trend: 2023 $294 · 2024 $437 · 2025 $710
Food & beverage: $710
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 13 | $278 |
| ABBVIE INC. | 12 | $244 |
| Novo Nordisk Inc | 1 | $61 |
| Otsuka America Pharmaceutical, Inc. | 2 | $55 |
| Axsome Therapeutics, Inc. | 2 | $34 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
Products named: CAPLYTA, VRAYLAR, Wegovy, REXULTI, Auvelity, INGREZZA, Qelbree.
Industry payments across AR — which companies pay providers there.
